Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06710756 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lead-212 PSV359 Therapy for Patients With Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 11 → 16 locations Eligibility criteria expanded, about 20 words · Secondary endpoints: details revised at 3 of 6 entries · Study description revised · 1 more Show 4 more changesShow less
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 3 of 6 entries
    • Study description revised
    • Publications: details revised at 1 of 1 entry
  2. Trial sites expanded: 8 → 11 locationsv7
  3. Study sites: 7 to 8v6
  4. Trial sites expanded: 3 → 7 locationsv5
  5. Study sites: 2 to 3v4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary endpoints revised (3) Study sites: 1 to 2 · Secondary endpoints: details revised at 4 of 6 entries · Study description revisedv3 Show 3 more changesShow less
    • Study sites: 1 to 2
    • Secondary endpoints: details revised at 4 of 6 entries
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jun 30, 2025 to Apr 28, 2025 · Secondary endpoints: 5 to 6 · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 30, 2025 to Apr 28, 2025
    • Secondary endpoints: 5 to 6
    • Study description expanded, about 187 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Perspective Therapeutics
3 trials monitored
See all monitored trials
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
Head & Neck Cancer
2,060 trials monitored
See 120 trials at risk
Pancreatic Cancer
1,639 trials monitored
See 91 trials at risk
and 5 more diseases
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Trial Details
NCT Number NCT06710756
Lead Sponsor Perspective Therapeutics
Conditions Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov